These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 11988845)

  • 1. Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI.
    Jennings D; Hatton BN; Guo J; Galons JP; Trouard TP; Raghunand N; Marshall J; Gillies RJ
    Neoplasia; 2002; 4(3):255-62. PubMed ID: 11988845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging.
    Galons JP; Altbach MI; Paine-Murrieta GD; Taylor CW; Gillies RJ
    Neoplasia; 1999 Jun; 1(2):113-7. PubMed ID: 10933044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts.
    Nicoletti MI; Lucchini V; D'Incalci M; Giavazzi R
    Eur J Cancer; 1994; 30A(5):691-6. PubMed ID: 7915909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model.
    Rozel S; Galbán CJ; Nicolay K; Lee KC; Sud S; Neeley C; Snyder LA; Chenevert TL; Rehemtulla A; Ross BD; Pienta KJ
    J Cell Biochem; 2009 May; 107(1):58-64. PubMed ID: 19259948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
    Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
    J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel (taxotere) in the treatment of prostate cancer.
    Beer TM; El-Geneidi M; Eilers KM
    Expert Rev Anticancer Ther; 2003 Jun; 3(3):261-8. PubMed ID: 12820771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
    Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel in prostate cancer.
    Small EJ
    Anticancer Drugs; 2001 Feb; 12 Suppl 1():S17-20. PubMed ID: 11340899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel in the integrated management of prostate cancer. Current applications and future promise.
    Logothetis CJ
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):63-72. PubMed ID: 12108899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemotherapy of prostate cancer: potential role of docetaxel].
    Bracarda S
    Tumori; 2001; 87(6):A12-4. PubMed ID: 11995697
    [No Abstract]   [Full Text] [Related]  

  • 12. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
    Picus J; Schultz M
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel.
    Huang SF; Kim SJ; Lee AT; Karashima T; Bucana C; Kedar D; Sweeney P; Mian B; Fan D; Shepherd D; Fidler IJ; Dinney CP; Killion JJ
    Cancer Res; 2002 Oct; 62(20):5720-6. PubMed ID: 12384530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
    Petrylak DP
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel chemotherapy response in PC3 prostate cancer mouse model detected by rotating frame relaxations and water diffusion.
    Laakso H; Ylä-Herttuala E; Sierra A; Jambor I; Poutanen M; Liljenbäck H; Virtanen H; Merisaari H; Aronen H; Minn H; Roivainen A; Liimatainen T
    NMR Biomed; 2021 Apr; 34(4):e4483. PubMed ID: 33543563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
    Yu DC; Chen Y; Dilley J; Li Y; Embry M; Zhang H; Nguyen N; Amin P; Oh J; Henderson DR
    Cancer Res; 2001 Jan; 61(2):517-25. PubMed ID: 11212244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future perspectives of docetaxel (Taxotere) in front-line therapy.
    Piccart MJ; Di Leo A
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-27-S10-33. PubMed ID: 9275004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice.
    Tang Y; Khan MA; Goloubeva O; Lee DI; Jelovac D; Brodie AM; Hussain A
    Clin Cancer Res; 2006 Jan; 12(1):169-74. PubMed ID: 16397039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel (Taxotere): preclinical and general clinical information.
    Earhart RH
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):8-13. PubMed ID: 10604262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.
    Fizazi K; Sikes CR; Kim J; Yang J; Martinez LA; Olive MC; Logothetis CJ; Navone NM
    Anticancer Res; 2004; 24(5A):2897-903. PubMed ID: 15517894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.